Hims & Hers Health/$HIMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Ticker
$HIMS
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
1,637
ISIN
US4330001060
Website
HIMS Metrics
BasicAdvanced
$10B
68.02
$0.68
2.10
-
Price and volume
Market cap
$10B
Beta
2.1
52-week high
$72.98
52-week low
$13.47
Average daily volume
47M
Financial strength
Current ratio
1.594
Quick ratio
1.176
Long term debt to equity
10.86
Total debt to equity
11.54
Profitability
EBITDA (TTM)
137.678
Gross margin (TTM)
77.04%
Net profit margin (TTM)
9.21%
Operating margin (TTM)
6.46%
Effective tax rate (TTM)
-37.22%
Revenue per employee (TTM)
$1,090,000
Management effectiveness
Return on assets (TTM)
10.77%
Return on equity (TTM)
36.79%
Valuation
Price to earnings (TTM)
68.02
Price to revenue (TTM)
5.656
Price to book
18.84
Price to tangible book (TTM)
26.66
Price to free cash flow (TTM)
42.673
Free cash flow yield (TTM)
2.34%
Free cash flow per share (TTM)
108.45%
Growth
Revenue change (TTM)
85.99%
Earnings per share change (TTM)
-6,216.96%
3-year revenue growth (CAGR)
77.17%
3-year earnings per share growth (CAGR)
23.27%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Bulls say / Bears say
Hims & Hers Health's acquisition of UK-based startup Zava expands its international presence, particularly in Germany, France, and Ireland, potentially increasing its customer base and revenue streams. (reuters.com)
The company reported a 110.7% year-over-year revenue increase in Q1 2025, reaching $586.01 million, surpassing analyst expectations and indicating strong financial performance. (reuters.com)
Hims & Hers Health's inclusion in the S&P SmallCap 600 index enhances its visibility among investors and may lead to increased stock demand. (reuters.com)
The U.S. FDA's ban on compounded versions of Novo Nordisk's weight-loss drug Wegovy has led Hims & Hers to cut 4% of its workforce, indicating potential challenges in its weight-loss product offerings. (reuters.com)
Citigroup reaffirmed a 'Sell' rating for Hims & Hers Health, suggesting concerns about the company's future performance and potential overvaluation. (marketbeat.com)
The discontinuation of its dermatology business, Apostrophe, may indicate operational challenges and could impact the company's diversification strategy. (businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
HIMS News
AllArticlesVideos
Class Action Announcement for Hims & Hers Health, Inc. (HIMS): Kessler Topaz Meltzer & Check, LLP
GlobeNewsWire·1 hour ago
HIMS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire·5 hours ago
Hims & Hers Health, Inc. (NYSE: HIMS) Accused of “Illegal Mass Compounding and Deceptive Marketing” Practices; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
Business Wire·16 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hims & Hers Health stock?
Hims & Hers Health (HIMS) has a market cap of $10B as of June 27, 2025.
What is the P/E ratio for Hims & Hers Health stock?
The price to earnings (P/E) ratio for Hims & Hers Health (HIMS) stock is 68.02 as of June 27, 2025.
Does Hims & Hers Health stock pay dividends?
No, Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Hims & Hers Health dividend payment date?
Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Hims & Hers Health?
Hims & Hers Health (HIMS) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.